With its business model, the Zur Rose Group offers high-quality, safe and cost-effective pharmaceutical care. It also excels in continuous development of digital healthcare services and as a platform technology provider. In addition, Zur Rose is actively driving forward its positioning as a comprehensive healthcare service provider, with focus on building up its European healthcare ecosystem networking qualified providers of products, services and digital solutions. Zur Rose's contribution will be to bring these offerings to customers and patients, pursuing its vision of creating a world where people can manage their own health in one click.

The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). For further information, please visit zurrosegroup.com.

^[1] External revenue consists of the consolidated revenue of the Zur Rose Group plus the mail-order revenue of pharmacies supplied by the Zur Rose Group, less the consolidated revenue for their supply. ^[2] Customers supplied by the Zur Rose Group, either directly or through its partners.

-----------------------------------------------------------------------------------------------------------------------

End of ad hoc announcement

----------------------------------------------------------------------------------------------------------------------- 


Language:     English 
Company:      Zur Rose Group AG 
              Walzmühlestrasse 60 
              8500 Frauenfeld 
              Switzerland 
Phone:        +41 52 724 08 14 
Internet:     www.zurrosegroup.com 
ISIN:         CH0042615283 
Listed:       SIX Swiss Exchange 
EQS News ID:  1242276 
 
End of Announcement EQS Group News Service 
=------------

1242276 21-Oct-2021 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1242276&application_name=news

(END) Dow Jones Newswires

October 21, 2021 00:56 ET (04:56 GMT)